State
72,919 recalls have nationwide distribution and so reach Ohio. 11,719 additional recalls listed Ohio specifically in their distribution scope.
Of the 11,719 recalls naming Ohio we have scored against our rubric, 2,106 (18%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 2,413 (21%) are Severe.
Which agencies issued them
These figures cover only the 11,719 recalls whose distribution notice names Ohio specifically. The 72,919 nationwide recalls listed below reach every state, so counting them here would make every state page show the same numbers.
GE Healthcare is recalling Omnipaque (iohexol) Injection, 350 mg/mL, over the presence of particulate matter. The action covers 306,810 vials distributed nationwide.
Viatris is recalling one lot of Xanax XR (alprazolam) extended-release tablets, 3 mg, after the product failed dissolution specifications.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP in 50 mL presentation, citing lack of assurance of sterility. Two batches are affected.
Fresenius Kabi is recalling one batch of 0.9% Sodium Chloride Injection, USP in 1,000 mL single dose freeflex bags distributed by BD, citing lack of assurance of sterility.
Fagron is recalling norepinephrine bitartrate 32 mg in 250 mL sodium chloride bags for lack of assurance of sterility and because a blue break-off part could detach from the administration port.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP supplied in 100 mL freeflex bags under its own label, citing lack of assurance of sterility.
Fresenius Kabi is recalling three batches of 5% Dextrose Injection, USP, 5 g per 100 mL in freeflex bags, citing lack of assurance of sterility.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP, 250 mL single dose freeflex bags distributed by BD, citing lack of assurance of sterility.
Fagron is recalling norepinephrine bitartrate 16 mg in 250 mL sodium chloride bags for lack of assurance of sterility and because a blue break-off part could detach from the administration port.
Winnebago is recalling 2027 Suncruiser and 2026-2027 Sunflyer motorhomes because side reflectors may be missing, reducing visibility to other drivers.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes for lack of assurance of sterility, following an FDA observation of deficiencies in visual inspection at the contract manufacturing site.
Cipla is recalling Lanreotide Injection 120 mg/0.5 mL prefilled syringes supplied with a safety needle, citing lack of assurance of sterility. 54,583 syringes are affected.
Blueroot Health, Inc. is recalling Vital Nutrients Aller-C vitamin supplements because they contain undeclared egg, soy, and hazelnut allergens, posing a risk to consumers with allergies to these ingredients.
Fresenius Kabi is recalling 0.9% Sodium Chloride Injection, USP in 1,000 mL single dose freeflex bags distributed by Fresenius Medical Care RTG, citing lack of assurance of sterility.
B.R.A.H.M.S PlGF Plus KRYPTOR in vitro diagnostic tests are being recalled after customers observed out-of-range values at the lowest quality control level, which can contribute to falsely elevated results.
Siemens ARTIS pheno and ARTIS Icono systems may sporadically display a major increase in the x-ray dose applied, although the actual dose applied remains within system settings and regulatory limits.
Ford is recalling certain 2021-2025 Bronco vehicles because a misaligned transmission to transfer case joint can wear the splines, potentially causing loss of drive power or rollaway.
Ford is recalling certain 2025-2026 F-59 and F-53 vehicles because the front axle hub assembly may be missing the spindle nut and cotter pin, which can lead to wheel detachment.
Ford is recalling 2015-2017 F-150 vehicles because a signal loss can cause unexpected downshifting, increasing crash risk. Dealers will update software free of charge.
Ford is recalling 2024-2026 Ranger vehicles because improperly positioned sun visor or headliner wiring harnesses may cause an electrical short and fire in the A-pillar area.
Ford is recalling certain 2026 Bronco Sport vehicles with a 1.5L or 2.0L MPC engine and block heater because the heater may overheat when plugged in while parked, increasing fire risk.
Harley-Davidson is recalling certain 2025–2026 Softail motorcycles because the rear brake line may contact the Body Control Module, causing a brake fluid leak and loss of rear brakes. Loss of rear brakes increases crash risk.
Jayco is recalling 2025-2026 Entegra Ethos recreational vehicles because incorrect seat belt labels may lead to unbelted passengers, increasing injury risk in crashes.
Hyundai Motor America is recalling certain Genesis GV70, G80, G90, and GV80 vehicles from 2021–2026 due to a fuel leak risk at the pipe connection between the fuel pipe and fuel rail, which increases the risk of fire.
Kia is recalling certain 2022–2026 Carnival vehicles because fuel may leak at the pipe connection between the fuel pipe and fuel rail, increasing the risk of fire.